- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01929226
Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
A Double-Blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of ETI-204 in Adult Volunteers
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
A double-blind, randomized, placebo-controlled study of a single IV dose of 16 mg/kg ETI-204 in adult volunteers (210 subjects ETI-204; 70 subjects placebo).
The total duration of the study for each subject will be approximately 100 days divided as follows:
Screening: Days -28 to -2; In-unit Phase: Day -1, Day 1, and Day 2; Out-of-unit Visits: Day 8 (±2 days); Day 15 (±3 days); Day 29 (±3 days); Day 43 (±3 days); Final Visit: Day 71 (±4 days).
Following completion of a screening visit subjects who qualify for entry into the study will be randomized to receive either ETI-204 or matching placebo on Day 1 in a 3:1 ratio. Subjects will be discharged from the clinic on Day 2 following completion of study assessments and will return for five additional visits on Days 8, 15, 29, 43 and 71.
The first 12 subjects will be dosed in groups of no more than 4 subjects/day. A blinded safety review of the available clinical and laboratory AE data up to and including Day 2 will be completed for the first 12 subjects before any additional subjects are dosed. This review will be conducted by the Investigator in conjunction with the Clinical Trial Steering Committee. If the outcome of this review is satisfactory, dosing of additional subjects will be permitted to continue and subjects may be dosed in group sizes larger than 4.
After Amendment 1, premedication with 50 mg oral diphenhydramine approximately 30 minutes prior to the start of study drug infusion was required.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Texas
-
Dallas, Texas, Forente stater, 75247
- Covance Clinical Research Inc.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Females or males ≥ 18 years of age
- All females, regardless of childbearing potential, must have a negative serum beta human chorionic gonadotropin (β-hCG) pregnancy test at Screening and Day -1
- Females of childbearing potential (i.e., not postmenopausal or surgically sterile) must agree to practice abstinence or to use a medically accepted method of contraception from the time of Screening through 30 days after final study visit. Acceptable methods of contraception include diaphragm with spermicide; sponge with spermicide; condom with spermicide; or intrauterine device with condom or spermicide. The following contraceptive methods are acceptable only when used with a condom and spermicide: birth control pills, birth control patches, vaginal ring, hormone under the skin, or hormone injections
- Postmenopausal females, defined as females who have had amenorrhea for at least 12 months either naturally or following cessation of all exogenous hormonal treatments and have a follicle stimulating hormone (FSH) level of > 40 mIU/mL at Screening
- Females who have undergone surgical sterilization, including hysterectomy, bilateral oophorectomy, bilateral salpingectomy, tubal ligation, or tubal essure
- Males must agree to practice abstinence or use a condom with spermicide and refrain from sperm donation during the study and for 30 days after the final study visit
- Provide written informed consent
- Willing to comply with study restrictions
Exclusion Criteria:
- Pregnant or lactating woman
- Clinically significant comorbidity that would interfere with completion of the study procedures or objectives, or compromise the subject's safety
- Seated systolic blood pressure (BP) ≥ 150 mmHg or ≤ 90 mmHg or diastolic BP ≥ 95 mmHg
- Use of H1 receptor antagonists (i.e. antihistamines) within 5 days prior to Day 1
- Evidence of drug or alcohol abuse as determined by the Investigator within 6 months of Day 1
- Positive test result for drugs of abuse (with the exception of medically prescribed drugs) at Screening or on Day -1
- Positive test for alcohol at Screening; exclusion is subject to the Investigator's discretion; subjects who test positive for alcohol at Day -1 are excluded from the study
- Treatment with an investigational agent within 30 days of Day 1 or within five half-lives of the investigational agent at Day 1 (whichever is longer)
- Congenital or acquired immunodeficiency syndrome
- Prior solid organ or bone marrow transplant
- Positive test for Hepatitis B (surface antigen), Hepatitis C, or human immunodeficiency virus (HIV) at Screening
- History of prior treatment for anthrax exposure or prior anthrax infection
- Prior immunization with any approved or investigational anthrax vaccine or prior treatment with an investigational anthrax treatment (i.e., ETI-204, raxibacumab, or anthrax immune globulin)
- Military personnel deployed in 1990 or after, unless the subject can provide documentation demonstrating they have not previously received any approved or investigational anthrax vaccine
- Use of systemic steroids, immunosuppressive agents, anticoagulants, or anti-arrhythmics within 1 year prior to Day 1. A single short course (i.e., less than 14 days) of systemic steroid therapy is allowed provided it concluded more than 6 months prior to Day 1
- Donation or loss of > 500 mL of blood within 30 days or plasma within 7 days of Day 1
- Prior stroke, epilepsy, relapsing or degenerative central nervous system disease, or relapsing or degenerative ocular disease
- Myocardial infarction or acute coronary syndrome in the past 5 years, active angina pectoris, or heart failure (New York Heart Association scale > 1)
- History of chronic liver disease
- Calculated creatinine clearance (CrCl) of < 30 mL/min using the Cockcroft-Gault equation
- Any clinically significant abnormality, in the Investigator's opinion, on electrocardiogram (ECG) or clinical laboratory tests (hematology, clinical chemistry, or urinalysis) at Screening; Out of range results may be repeated to confirm.
- History of allergic or hypersensitivity reactions to other therapeutic antibodies or immunoglobulins
- History of any malignant neoplasm within the last 5 years, with the exception of adequately treated localized or in situ non-melanoma carcinoma of the skin (i.e., basal cell carcinoma) or the cervix
- Subjects who, in the opinion of the Investigator, are not suitable candidates for enrollment or who may not comply with the requirements of the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: ETI-204
A single intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1
|
Monoclonal Antibody
|
Placebo komparator: Placebo for ETI-204
A single intravenous dose of ETI-204-placebo infused over 90 minutes on Day 1
|
Placebo for ETI-204
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants Who Experienced Adverse Events
Tidsramme: Up to 71 days or 101 days (30 days after the final study visit) for subjects with ongoing adverse events at the final study visit, for each group.
|
Safety was assessed for all subjects in the safety population by collecting and monitoring vital signs, clinical laboratory tests, ECGs, physical examinations, skin assessments, infusion site assessments, and adverse events.
|
Up to 71 days or 101 days (30 days after the final study visit) for subjects with ongoing adverse events at the final study visit, for each group.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Maximum Observed Plasma Concentration of ETI-204 (Cmax)
Tidsramme: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Time to Maximum Observed Plasma Concentration of ETI-204 (Tmax)
Tidsramme: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUC0-last)
Tidsramme: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf)
Tidsramme: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Terminal Half-life (t1/2)
Tidsramme: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Systemic Clearance (CL)
Tidsramme: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Volume of Distribution (Vd)
Tidsramme: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Volume of Distribution at Steady State (Vss)
Tidsramme: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Number of Participants With Anti-ETI-204 Antibodies
Tidsramme: On Day 1 prior to the start of infusion and on Days 8, 43, and 71.
|
Serum anti-ETI-204 antibody titers were determined for all subjects in the safety population.
Blood samples were collected and serum samples were assayed at an initial dilution of 1:10.
Samples that were positive at the 1:10 dilution were serially diluted 1:2 and assayed until a negative result was attained.
The titer of the most dilute sample yielding a positive result was recorded as the titer for that time point.
Immunogenicity was measured by the number of participants in each study arm with anti-ETI-204 antibody values post-treatment ≥ 4-times higher than baseline at Day 8, 43 or 71, or if the titer was negative at baseline, the post-treatment sample(s) required a titer of at least 1:20 for it to be considered positive.
|
On Day 1 prior to the start of infusion and on Days 8, 43, and 71.
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Alex King, MD, Covance
- Hovedetterforsker: Lori Sieboldt, MD, Covance Clinical Research - Evansville, IN
- Hovedetterforsker: Debra Mandarino, MD, Covance Research, Madison, WI
- Hovedetterforsker: H. Frank Farmer, PhD, MD, Covance Research - Daytona Beach, Fl
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- AH104
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Inhalasjonsmiltbrann
-
PharmAthene UK LimitedNational Institute of Allergy and Infectious Diseases (NIAID)FullførtForebygging av Bacillus Anthracis (Anthrax) infeksjonStorbritannia
Kliniske studier på ETI-204
-
Elusys TherapeuticsFullførtFriske FrivilligeForente stater
-
Elusys TherapeuticsFullførtInhalasjonsmiltbrannForente stater
-
University of AarhusRekrutteringCystisk fibrose (CF) | CFTR-genmutasjonDanmark
-
Wyeth is now a wholly owned subsidiary of PfizerAvsluttetSukkersykeKina, Forente stater, Canada, Mexico, Den russiske føderasjonen, Kroatia, Storbritannia, Argentina, Australia, India, Sør-Afrika, Hellas, Ukraina, Romania, Italia, Hong Kong, Tidligere Serbia og Montenegro, Brasil
-
Ohio State UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of UtahHar ikke rekruttert ennåSår og skader | Kritisk sykdom | Bare barn | Hjertestans, Utenfor sykehus | Respiratorisk insuffisiens hos barn
-
Elusys TherapeuticsFullførtInhalasjonsmiltbrannForente stater
-
ACADIA Pharmaceuticals Inc.Har ikke rekruttert ennåAlzheimers sykdom psykoseForente stater
-
Wyeth is now a wholly owned subsidiary of PfizerFullført
-
TScan Therapeutics, Inc.RekrutteringMelanom | Livmorhalskreft | Hode- og nakkekreft | HPV-relatert malignitet | Eggstokkreft | HPV-relatert karsinom | HPV-relatert livmorhalskreft | HPV-positivt orofaryngealt plateepitelkarsinom | Ikke-småcellet karsinom | HPV - Anogenital Human Papilloma Virus Infeksjon | HPV-relatert adenokarsinom | HPV-relatert... og andre forholdForente stater
-
National Institute of Allergy and Infectious Diseases...FullførtBacillus Anthracis (miltbrann)Forente stater